Identification and validation of platinum resistance signature in gastric cancer

Title	Identification and validation of platinum resistance signature in gastric cancer
Authors	Wenjing Yan, Nan Zhu, Yupeng Zhao, Qingqing Sang, Jianfang Li, Bingya Liu, Zhongyin Yang, Beiqin Yu
Magazine	Cancer Cell International
Date	04/13/2025
DOI	10.1186/s12935-025-03777-z
Introduction	Platinum-based drugs, combined with fluoropyrimidine, are standard for treating gastric cancer (GC). However, drug resistance remains a significant challenge. This study focuses on identifying and validating platinum-related genes in GC to develop a multi-gene signature predicting patient prognosis. Utilising 326 platinum-related genes, GO and KEGG analyses highlighted pathways associated with platinum resistance. A 21-gene model was constructed using UniCox and Lasso-Cox regression analyses, offering predictive value across various patient demographics. The model was validated through stratified analysis, revealing significant CNV changes in the score-high group and correlations with TMB, MSI, and HLA gene expressions. In vitro and in vivo models confirmed the upregulation of these genes under chemotherapy pressure, underscoring the need to further explore the clinical applications of the platinum resistance signature.
Quote	Wenjing Yan, Nan Zhu and Yupeng Zhao et al. Identification and validation of platinum resistance signature in gastric cancer. Cancer Cell Int. 2025. Vol. 25. DOI: 10.1186/s12935-025-03777-z
Element	Platinum (Pt)
Industry	Chemical & Pharmacy